Introduction
Although the concentration of the serum copper protein ceruloplasmin is decreased in most patients with Wilson's disease (1) , there are several objections to the theory that decreased ceruloplasmin synthesis (2) is the underlying defect. There are, for instance, several patients with unquestionable Wilson's disease who have normal ceruloplasmin levels (3) (4) (5) . On (6) .
These findings are consistent with the hypothesis that the ceruloplasmin in patients with Wilson's disease is structurally abnormal (7) . An amino acid substitution in a polypeptide chain of ceruloplasmin, as in other proteins, could alter the function, the rate of synthesis or destruction of the protein, or both. The genetic heterogeneity in * Submitted for publication October 21, 1966; ac- Wilson's disease (8) could be explained if, in one pedigree, an amino acid substitution occurs at a point in one of the polypeptide chains, resulting in a limited alteration of function, whereas in another pedigree an amino acid substitution at a different point results in a more profound disturbance.
Ceruloplasmin accounts for the oxidase activity of serum towards several biological aromatic amines in vitro (9) . However, its function in vivo is still unknown. In previous studies (1, 10, 11) , insufficient data were presented to determine if the oxidase activity per milligram of ceruloplasmin in sera from patients with Wilson's disease differs significantly from normal. Furthermore, these studies were performed on serum, in which inhibitory factors occur in variable amounts (12) , and therefore may not accurately compare the oxidase activity per mole of pure ceruloplasmin in Wilson's disease to that of ceruloplasmin in normal individuals.
Structural differences of ceruloplasmin in Wilson' disease sera have not been detected either by one dimensional electrophoresis (13) (14) (15) or by immunolectrophoresis (16 (measured by its oxidase activity) was 25 mg per 100 ml, low normal for this laboratory (19) . An increase in urinary amino acids, consistent with a generalized renal tubular defect, was found.
One g per day of D-penicillamine was begun. In the second 24 hours, the patient excreted 4,502
MAg copper in the urine. This cupuresis was maintained over the next 9 weeks, after which urine collections were discontinued. The daily dosage was increased to 4 g. After 3j months of penicillamine, the serum ceruloplasmin concentration had fallen to 8 mg per 100 ml. Three months later none was detectable.
After the patient had been receiving penicillamine for 2 months, a closed liver biopsy was performed. Liver copper was 114 ,ug per g wet weight (normal value = less than 15 Mug per g wet weight). The biopsy showed moderate fibrosis and regenerating nodules. There was no necrosis.
There was no clinical improvement for the first 9 months on penicillamine therapy, but over the next month progressive improvement, with almost complete disappearance of tremor and speech changes, occurred. The patient felt so well that he failed to return for medicine until approximately 1 year after his first admission, when he noted some recurrence of tremor. He was readmitted at this time and aside from some mild intention tremor of the upper extremities, where the deep tendon reflexes were hypoactive, and the persis-tent Kayser-Fleischer rings, physical examination was unremarkable. His ceruloplasmin was now 4 mg per 100 ml. D-Penicillamine, 4 g per day, was again started, resulting in the renal excretion of 3,710 jug copper on the second day.
A plasmapheresis, yielding 600 ml of heparinized plasma, was performed on the patient 1 week after he was started on penicillamine for the first time. A second plasmapheresis, yielding 800 ml of plasma, was performed about 1 year later before penicillamine therapy was reinstituted. There were no ill effects from the procedure. Ceruloplasmin was purified from the plasma obtained.
In Separation on hydroxylapatite. Cer5.s was dialyzed against 0.05 M potassium phosphate, pH 6.4, and applied to a 20-X 1-cm column of hydroxylapatite (21) . The variable gradient multichamber device was employed for elution with 80 ml of 0.05 M potassium phosphate, pH 6.4, in the first chamber, 80 ml of 0.20 M phosphate, pH 6.4, in the next three chambers, and 80 ml of 0.40 M phosphate, pH 6.4, in the last chamber. Two ceruloplasmin components, HA I and HA II, were eluted (Figure 1 , bottom). Each of these was concentrated to a gelatinous pellet in a Schleicher and Schuell collodion bag under water vacuum overnight at 0 to 40 C. The pellets were dissolved in 0.35 M sodium acetate, pH 5.8, and passed through 0.45-,g Millipore filters.
Assays. Ceruloplasmin concentration was determined either by assay of oxidase activity (19) or by its ODemo mp, 1 cm using Eno m0%, 1 cm, 1% = 0.68 (20 (24) and determined by a modified ElsonMorgan procedure (25) . The neutral sugars contained in the wash from the Dowex 50 column used in the preparation of glucosamine were further purified by the addition of Dowex 1 to the wash until no chloride was detectable. The resin was removed by filtration. The filtrate was concentrated and applied over a 2-inch band to Whatman 1 chromatography paper and run by the descending method overnight in n-butanol: acetic acid: water (12: 3:5) . A *-inch guide strip from each sample was stained by the silver nitrate method (26) , and the bands corresponding to the stained areas were cut out of the unstained paper and eluted with water. The stained areas had Rf identical to fucose, mannose, and galactose. A blank area of paper was eluted for use as an internal background in the determination of "4C in each of the eluted fractions and in the determination of fucose by the method of Dische and Shettles (27) . Mannose and galactose were determined on the eluents from the paper by the Nelson method (28) with standards of mannose and galactose, respectively.
Electrophoresis. Vertical starch gel electrophoresis (29) was performed in a continuous system at pH 5.6 (0.03 M sodium acetate) and at pH 6.4 (0.0054 M sodium phosphate) with the wicks immersed in 0.04 M sodium phosphate, pH 6.4. Electrophoretic comparisons were also made in acrylamide in a discontinuous system at pH 8.9 (30) in a new device which permitted nine samples to be run in one slab (31) . The gels were stained either for protein (29) or oxidase (ceruloplasmin) with 0.1% benzidine in 0.3 M sodium acetate, pH 5.2.
Tryptic digests. To reduce the size of the trypsin-resistant core, we aminoethylated the purified protein (32) . After reduction for 3 hours with 0.04 M mercaptoethanol in 8 M urea and 1 M Tris-HCl, pH 9.1, ethylene imine was added to a final concentration of 0.50 mole per L.
After 2 hours the nitroprusside test (33) for free sulfhydryl was still positive, and ethylene imine was again added to a final concentration of 1 mole per L. The incubation continued for a total of 16 to 20 hours at room temperature, at which time no free sulfhydryl was detectable. The samples were desalted by passage through Sephadex G-25 columns equilibrated with 0.025 N NH40H and lyophilized.
The dried protein was suspended in 1% (NH4)2COs, and 20 Ag trypsin per mg protein was added. Digestion at 300 C with 0.005 ml toluene present continued for 16 hours and was terminated by repeated lyophilization to remove (NH4)2CO3 (34) . Tryptic peptide maps were performed on 2.5 to 3 mg of digest by the method of Ingram (35) , except that chromatographic separation employed a solvent of n-butanol: acetic acid: water: pyridine (15: 3: 12: 10) (36) in either the ascending or descending direction. The resulting maps were stained with Ninhydrin and with stains specific for histidine or methionine (37) .
Results
Chromatographic purification of ceruloplasmin from the plasma of our patient with Wilson's disease when his ceruloplasmin concentration was 4 mg per 100 ml is shown in Figure 1 , top, together with a purification of ceruloplasmin from plasma of normal subjects. Because of the reduced ceruloplasmin concentration in the patient's plasma, the protein eluting just after ceruloplasmin became a major contaminant. The protein was completely removed from the ceruloplasmin fraction, however, by passage over hydroxylapatite (Figure 1,  bottom) . As shown, the ceruloplasmin from the patient with Wilson's disease was eluted from both DEAE-Sephadex and hydroxylapatite at the same ionic strength, measured by conductivity, as ceruloplasmin from normal subjects. Blue crystals, consisting of tetragonal needles and rosettes, were obtained from both Wilson's disease and normal ceruloplasmin.
The ratio of absorbance at 280 my, to 610 m~u of crystalline electrophoretically pure ceruloplasmin is 22 to 23 (38) . In Table I which were at least 3 months old (stored at 4 to 100 C) at the time of electrophoresis and which had been prepared slightly differently (sample 1 in Figure 2 , samples 4 and 5 in Figure 3 ) showed a mobility of ceruloplasmin different from freshly prepared ceruloplasmin from either normal or Wilson's disease subjects. Such alterations of aged preparations were reported previously (39) . Sample 8 in Figure 2 represents partially purified ceruloplasmin from a second unrelated patient with Wilson's disease who, so far as known, always had a low serum ceruloplasmin concentration. His ceruloplasmin chromatographed 
FIG. 3. STARCH GEL ELECTROPHORESIS, PH 6.4, OF CERULOPLASMIN PREPARATIONS STAINED FOR
PROTEIN. Slots 1 and 3 = ceruloplasmin from normal subjects. Slot 2 = ceruloplasmin from E.C. The preparation procedures for samples 1 to 3 were identical; the preparations were made within 1 month of each other. Slots 4 and 5 = aged ceruloplasmin preparations from two other normal subjects. These were prepared and stored at pH 5.5 rather than 5.8.
normally on DEAE-Sephadex and had a normal electrophoretic mobility at pH 6.4. We have confirmed the slower electrophoretic mobility at pH 5.6 (17) of the purified minor ceruloplasmin component eluted from hydroxylapatite (HA II), but we could not show any difference between the mobility of this component from our patient with Wilson's disease and that from normal subjects (Figure 4) (38) . (19) , it is possible that the defect in this patient is a diminished -but not absent-sensitivity of the ceruloplasminsynthesizing system to copper. As body copper was lowered with penicillamine, the attenuated stimulus for synthesis was removed. The reappearance of some ceruloplasmin after penicillamine was discontinued is consistent with this theory.
It would appear even less fruitful to look for an amino acid alteration in ceruloplasmin as the underlying defect in those patients with Wilson's disease in whom the ceruloplasmin is persistently low. In one such patient from whom ceruloplasmin was partially purified, we could detect no abnormality electrophoretically. When penicillamine was temporarily discontinued in this patient, ceruloplasmin rose from less than 2 to 6.5 mg per 100 ml after 31 months.
Without establishing the sequence of amino acids of the entire ceruloplasmin molecule we cannot completely eliminate the possibility of an alteration in amino acid composition. Such an alteration, however, would have to be an isoelectric substitution and would most likely be in the insoluble core, which is less than 10% of the total protein.
This study failed to confirm a report (17) of an increased electrophoretic mobility of the minor ceruloplasmin component (HA II) purified on hydroxylapatite from a patient with Wilson's disease. In that study HA II purified from normal umbilical cord blood had the same electrophoretic mobility as HA II from a patient with Wilson's disease. Both were electrophoretically faster than HA II from normal adults. In that study, however, one step in purification used in preparing ceruloplasmin from normal adults was omitted in the preparation of ceruloplasmin from the patient with Wilson's disease and also from normal cord blood. This difference in procedure may account for the different mobilities of the minor component. We have observed alteration in mobility associated with minor changes in purification and after refrigeration (4 to 100 C) for periods of more than 3 months.
The current study, together with those of Hirschman and associates (17) and Broman (49) , fails to confirm Richterich, Gautier, Stillhart, and Rossi's report (50) that patients with Wilson's disease have only the minor ceruloplasmin component. The relation of the minor ceruloplasmin component to the major one is unclear. Although it has an additional peptide, it is uncertain if its structure is determined by a different gene from that which determines the structure of the major component (43) . The tryptic peptide map of the minor component in our patient with Wilson's disease is indistinguishable from the normal minor component. There was, unfortunately, insufficient quantity to determine copper or sugar composition of this component.
